Not exact matches
In a clinical trial published in June, melanoma patients who received
ipilimumab combined with chemotherapy gained a precious extra few months» survival compared with those who received chemo alone, and the treatment nearly doubled the number of patients still
living after three years.
Ipilimumab often triggers colitis, an inflammation of the large intestine, where part of our microbiome
lives.
Last year the Food and Drug Administration approved Benlysta (belimumab), the first new treatment for systemic lupus erythematosus in more than 50 years, and Yervoy (
ipilimumab), the first drug shown to prolong the
lives of patients with melanoma.
Advanced melanoma patients successfully treated with a combination of nivolumab and
ipilimumab may endure severe side effects, but they do not suffer any clinically meaningful changes in health - related quality of
life.